Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma

HPB

Volumn 16, Issue 8, 2014, Pages 758-767

  Ho, Edith Y ^a   Cozen, Myrna L ^a,b   Shen, Hui ^a,b   Lerrigo, Robert ^a   Trimble, Erica ^b   Ryan, James C ^a,b   Corvera, Carlos U ^a,b   Monto, Alexander ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RADIOFREQUENCY ABLATION; SURVIVAL TIME; TERTIARY CARE CENTER; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CALIFORNIA; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SAN FRANCISCO; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904302307     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12214     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Centers for Disease Control and Prevention. (2010) Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Wkly Rep 59: 517-520.
3. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE,. (2010) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 55: 476-482.
4. Altekruse SF, McGlynn KA, Reichman ME,. (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491.
5. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB,. (2004) Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127: 1372-1380.
6. Center for Quality Management in Public Health. (2010) The State of Care for Veterans with Chronic Hepatitis C. Palo Alto, CA: Public Health Strategic Health Care Group, US Department of Veterans Affairs, Health CfQMiP.
7. Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, et al. (2013) Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and non-patient factors. Hepatology 57: 1858-1868.
8. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL, et al. (2005) Elevated prevalence of hepatitis C infection in users of United States veterans medical centres. Hepatology 41: 88-96.
9. Lurje G, Lesurtel M, Clavien PA,. (2013) Multimodal treatment strategies in patients undergoing surgery for hepatocellular carcinoma. Dig Dis 31: 112-117.
10. Belghiti J,. (2009) Resection and liver transplantation for HCC. J Gastroenterol 44 (Suppl. 19): 132-135.
11. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. (2011) Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 154: 85-93.
12. Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF,. (2011) Underutilization of therapy for hepatocellular carcinoma in the Medicare population. Cancer 117: 1019-1026.
13. Llovet JM,. (2002) Evidence-based medicine in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 17 (Suppl. 3): 428-433.
14. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171.
15. Poon RT, Fan ST, Lo CM, Liu CL, Wong J,. (2002) Longterm survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235: 373-382.
16. Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC, et al. (2012) Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol 10: 1284-1290.
17. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-700.
18. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumour size limits does not adversely impact survival. Hepatology 33: 1394-1403.
19. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7: 350-391.
20. Bruix J, Sherman M,. (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
21. D'Avola D, Inarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI, et al. (2011) Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol 18: 1964-1971.
22. Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. (2011) Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 18: 1624-1629.
23. Piscaglia F, Bolondi L,. (2010) The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 42 (Suppl. 3): 258-263.
24. Bruce-Chwatt LJ,. (1965) Declaration of Helsinki. Recommendations Guiding Doctors in Clinical Research. WHO Chron 19: 31-32.
25. Schuckit MA,. (2009) Alcohol-use disorders. Lancet 373: 492-501.
26. Child CGI, ed. (1964) The Liver and Portal Hypertension. Vol. 1 of Major Problems in Clinical Surgery. Philadelphia, PA: W B Saunders.
27. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC,. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871.
28. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649.
29. Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, et al. (2008) Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB 10: 405-411.
30. Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ,. (2010) Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg 145: 1158-1163.
31. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8: 773-783.
32. Colombo M, Raoul JL, Lencioni R, Galle PR, Zucman-Rossi J, Banares R, et al. (2013) Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol 25: 639-651.
33. Silva MF, Sapisochin G, Strasser SI, Hewa-Geeganage S, Chen J, Wigg AJ, et al. (2013) Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC patients with a single nodule up to 5 cm: a multicentre, exploratory analysis. Eur J Surg Oncol 39: 386-395.
34. Giuliante F, Ardito F, Pinna AD, Sarno G, Giulini SM, Ercolani G, et al. (2012) Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicentre study on 588 patients. J Am Coll Surg 215: 244-254.
35. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, et al. (2011) Which matters most: number of tumours, size of the largest tumour, or total tumour volume? Liver Transpl 17 (Suppl. 2): 58-66.
36. Tiong L, Maddern GJ,. (2011) Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 98: 1210-1224.
37. Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, et al. (2011) Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 18: 228-240.
38. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. (2012) Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 32: 348-359.